The detection of multidrug resistant mycobacterium tuberculosis by using genotype MTBDRplus (Hain's Test)

Abstract

Tuberculosis (TB) ) is highly infectious and still remains a global health problem although improvements in diagnostic, drug susceptibility tests [1,2] and supported national programs. The emergence of strains resistant to the major anti-TB drugs speed up the need for rapid methods for the detection of MDR-TB to treat disease effectively and, at the same time, prevent the spread of resistant strains. In order to increase the ability to detect RIF and INH resistance, a new version of the GenoType MTBDR assay, the GenoType MTBDRplus assay, that covers more mutations has recently been developed. The GenoType MTBDRplus assay targets the mutations included in the previous test and includes a broader selection of probes for the wild-type rpoB gene and the hot spot region (of the rproB mutation1=MUT1; mutation2A=MUT2A; mutation 2B=MUT2B; mutation 3=MUT3, and a base-pair change in codon 315 of the katG gene with MUT1; MUT2, followed by mutations in position -15 of the inhA gene promoter region: inhA MUT1; MUT2, MUT3A; MUT3B. The purpose of this project is to apply GenoType MTBDRplus test (Hain Lifescience GmbH, Nehren, Germany) as a rapid diagnostic tool to predict INH and/or RIF resistance directly applied from smear-positive clinical specimens. Key words: Tuberculosis, GenoType MTBDRplus, Multidrug-resistance, Rifampicin (RIF), Isoniazid (INH).